Internal Reference Number: FOI_7691
Date Request Received: 22/01/2024 00:00:00
Date Request Replied To: 23/02/2024 00:00:00
This response was sent via: By Email
Request Summary: GCA and HS
Request Category: Researcher
Question Number 1: Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Bimekizumab • Certolizumab • Infliximab • Secukinumab • Ustekinumab | |
Answer To Question 1: • Adalimumab - Humira <5 • Adalimumab Biosimilar 0 • Bimekizumab 0 • Certolizumab 0 • Infliximab 0 • Secukinumab 0 • Ustekinumab 0 | |
Question Number 2: In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were: • Admitted as an inpatient • Treated in A&E | |
Answer To Question 2: Admitted as an inpatient = <= 5 Treated in A&E = <=5 | |
Question Number 3: How many patients were treated by the rheumatology department in the past 3 months with the following: • Tocilizumab – for any disease • Tocilizumab for rheumatoid arthritis (RA) only • Tocilizumab for giant cell arteritis (GCA) only | |
Answer To Question 3: • Tocilizumab – for any disease = 50 patients • Tocilizumab for rheumatoid arthritis (RA) only = 30 patients • Tocilizumab for giant cell arteritis (GCA) only = <5 patients | |
Question Number 4: How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? | |
Answer To Question 4: 0 - the drug is given by Rheumatology. | |
Question Number 5: How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab? | |
Answer To Question 5: 0 | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.